GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Stock Based Compensation

TheraCryf (FRA:8EV) Stock Based Compensation : €0.12 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Stock Based Compensation?

TheraCryf's Stock Based Compensation for the six months ended in Sep. 2024 was €0.03 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 was €0.12 Mil.


TheraCryf Stock Based Compensation Historical Data

The historical data trend for TheraCryf's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Stock Based Compensation Chart

TheraCryf Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 -0.13 0.18 0.18 0.16

TheraCryf Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.11 0.06 0.10 0.03

TheraCryf Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.12 Mil.


TheraCryf Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of TheraCryf's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf Business Description

Traded in Other Exchanges
Address
Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

TheraCryf Headlines

No Headlines